Prospective Feasibility Study Evaluating EchoMark LP Placement and EchoSure Measurements for Subjects Requiring Arteriovenous Fistulae

Completed · Not applicable

Conditions studied: Kidney Diseases, Arteriovenous Fistula

In brief

Multi-center trial to assess the feasibility and safety of the EchoMark LP and the EchoMark diagnostic ultrasound system for assessing AV fistula blood flow, diameter, and depth.

Key facts

Study ID

NCT04896476

Run by

Sonavex, Inc.

People needed

20

Starts

2022-01-21

Expected to finish

2026-04-30

Last updated by the study team

2026-05-20

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or non-pregnant, non-breastfeeding females ≥ 18 years of age but < 85 years of age at the time of informed consent
• Subject is able and willing to provide written informed consent prior to receiving any non-standard of care, protocol specific procedures
• Subject is willing and capable of complying with all required follow-up visits
• Subject and/or Care Team agree that the distance and transportation resources from the subject's home to the clinic are reasonable for study participation and compliance
• Subject has an estimated life expectancy > 18 months
• Subject is ambulatory (cane or walker are acceptable)
• Subjects presenting for upper arm autologous arteriovenous fistula creation
• Vein diameter > 2.5 mm at the antecubital fossa via imaging
• Artery diameter > 3 mm via imaging
• Subject is not participating in another investigational clinical trial that has not met its primary endpoint. Participation in a post-market registry is acceptable.

You may not qualify if…

• Subjects receiving a forearm fistula.
• Subject has history of Steal Syndrome.
• Subject who is immunocompromised or immunosuppressed.
• Subject has had three previous failed AV fistulae for hemodialysis access
• Subjects expecting to undergo major surgery within 60 days from the EchoMark implantation.
• Known or suspected active infection on the day of the index procedure.
• Subjects who had infection(s) in the 30-day window prior to EchoMark placement to reduce the likelihood of partially treated infections that can seed the device and fistula
• Subjects with diagnosed bleeding disorder, thrombocytopenia (platelet count <50,000), hypercoagulability, and history of recurrent deep vein thrombosis not related to AV access
• Subjects with active malignancy
• Subjects with a history of poor compliance with the dialysis protocol
• Subjects with a known or suspected allergy to any of the device materials
• Subjects with an existing fistula or graft
• Subjects who are pregnant, plan to become pregnant, or are breastfeeding.

Where it is running

• Trinity Research Group — Dothan, Alabama, United States
• SKI Vascular Center — Peoria, Arizona, United States
• Michgan Vascular Center — Flint, Michigan, United States
• Surgical Specialist of Charlotte — Charlotte, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.